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Background and Purpose:  We examined blood pressure 1 year after stroke discharge and its 
association with treatment intensification.    
Methods: We examined the systolic blood pressure (SBP) stratified by discharge SBP (<140; 
141 to 160; or >160 mmHg) among a national cohort of Veterans discharged after acute ischemic 
stroke. Hypertension treatment opportunities were defined as outpatient SBP >160 mm Hg or 
repeated SBPs >140 mm Hg. Treatment intensification was defined as the proportion of 
treatment opportunities with antihypertensive changes (range 0 to 100%, where 100% indicates 
that each elevated SBP always resulted in medication change).   
Results: Among 3153 ischemic stroke patients, 38% had at least one elevated outpatient SBP 
eligible for treatment intensification in the 1 year post stroke.  Thirty percent of patients had a 
discharge SBP <140mmHg; and an average 1.93 treatment opportunities and treatment 
intensification occurred in 58% of eligible visits.  Forty seven percent of patients discharged with 
SBP 141 to160 mmHg had an average of 2.1 opportunities for intensification and treatment 
intensification occurred in 60% of visits.  Sixty three percent of the patients discharged with an 
SBP >160mmHg had an average of 2.4 intensification opportunities, and treatment 
intensification occurred in 65% of visits.  
Conclusion:  Patients with discharge SBP >160mmHg had numerous opportunities to improve 
hypertension control.  Secondary stroke prevention efforts should focus on: initiation and review 
of antihypertensives prior to acute stroke discharge; management of antihypertensives and 
titration; and patient medication adherence counseling.  





Having a stroke increases risk for recurrent stroke.1, 2  Systolic blood pressure (SBP) remains the 
most modifiable risk factor for stroke and antihypertensive medications are efficacious in 
reducing SBP.3  Patients who experience a recent stroke may be more motivated to adhere to 
their medications and attain better risk factor control.  Conversely, a recent study of patients with 
a stroke demonstrated that 25% had discontinued at least one secondary prevention medication 
within 3 months of hospital discharge.4   
 
Given that hypertension is the risk factor with the greatest population attributable risk for stroke 
and is present in the majority of patients5, we were interested in examining the patterns of 
hypertension management in the one-year post-stroke period. Uncontrolled SBP after a stroke 
may be related to a variety of factors including non-adherence, inappropriate medication 
selection, clinical inertia, or resistant hypertension refractory to treatment.  The aim of this study 
was to determine whether some of these factors are associated with uncontrolled SBP.  We 
determined the quality of hypertension care after a stroke by describing:  (1) the patient’s SBP 
trajectory after stroke; (2) antihypertensive treatment intensification (proportion of treatment 
intensification opportunities [denominator] associated with medication intensifications 
[numerator]); and (3) the association between patient adherence and treatment intensification.  
This first step was important to understanding factors that impact uncontrolled hypertension in 
the post stroke period and in designing interventions to improve risk factors among ischemic 
stroke patients.  
 




Study Design and Data Sources 
The Office of Performance Measurement Stroke Special Study was a retrospective cohort of 
Veterans admitted during Fiscal Year 2007 with a primary diagnosis of ischemic stroke, 
identified using a modified high specificity algorithm of the International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (N=5721 possible stroke 
events).6-8  A systematic sample of 5000 records that included all ischemic stroke patients at 
hospitals with less than 55 stroke hospitalizations and an 80% random sample of patients at 
hospitals with more than 55 stroke hospitalizations were selected for abstraction.   Because of 
this sampling, the number of patients per hospital ranged from 1 to 198 (mean=38 and standard 
deviation [SD] =28).   Among the 307 data elements abstracted, 90% demonstrated good or very 
good interrater reliability [Kappa statistic ≥0.70].9  
 
Abstracted data was linked to Veterans Health Administration (VHA) outpatient treatment and 
pharmacy files.  Data on antihypertensive prescriptions dispensed included medication name, 
date filled, days supplied, quantity and dosage.  Vital signs data included all outpatient SBP 
measurements. Dates of death were obtained from VHA vital status files.   For Medicare eligible 
Veterans, we obtained supplemental race data from the Centers for Medicaid and Medicare 
Services. The study received institutional review board approval.  
 
Study Population 
Veterans were excluded if the hospitalization was for: rehabilitation, elective carotid 
endarterectomy, or another condition in which they experienced an in-hospital ischemic stroke.  
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We excluded patients who died during their index hospitalization, had hospice or long-term care 
or did not have post-discharge SBP values.   We included SBP from the following clinics: 
internal medicine; primary care/medicine; women’s health; mental health primary care; 
geriatrics; hypertension; cardiology; anticoagulation; diabetes/ endocrine; infectious disease; 
renal/nephrology; pulmonary/chest; or neurology. These clinics were chosen because these 
clinicians often manage BP by prescribing antihypertensive medications. 
 
Outcome: Clinically appropriate treatment intensification  
Clinically appropriate treatment intensification was defined as the proportion of medication 
intensifications (numerator) to medication intensification opportunities (denominator) of elevated 
SBP in the year post stroke.  This proportion could range from 0 to 100% where 100% 
represented a patient wherein every elevated SBP opportunity resulted in medication 
intensification.  
  
Antihypertensive Medication Intensification (Numerator)  
Medication intensification occurred if a new antihypertensive was added, a dose was increased, 
or a medication switch occurred within 30 days of an opportunity.  The date of the new 
prescription or dose change was the intensification date.  For validation, we randomly reviewed 
38 charts and correctly identified 12/12 patients who intensified therapy (positive predictive 
value 100%, 95% confidence intervals [CI] 75.8, 100).  We also predicted 21 out of 26 patients 
as not having intensified therapy (negative predictive value =80.8, 95% CI 62.1, 91.5).  We 
missed 5/26 patients (20%) in which the provider told the patient to change the dose and did not 
alter the prescription.   




Opportunities of Elevated BP (Denominator) 
A visit was a potential intensification opportunity if it satisfied one of three criteria:  (1) SBP 
>160 mm Hg, (2) the second of two consecutive visits where the SBP was >140 mmHg or (3) the 
SBP in which more than 50% of the preceding visits were >140 mm Hg.  If multiple BP 
measures were recorded on the same day, then the lowest BP was utilized.  We excluded SBPs 
considered data entry errors or improbable outpatient values; including, diastolic blood pressure 
(DBP) >SBP, SBP < 60 mmHg, DBP < 30mmHg, or SBP minus DBP <10mmHg.    
 
To allow medication changes to take effect and assure that the SBP was not falsely elevated; we 
excluded opportunities within 30 days after medication changes.  Because providers may request 
a repeat measurement on another day to confirm the elevated SBP, we excluded SBP measures 
between 141 and 160 mmHg, if there was another value <140mmHg within 7 days.  This 
approach was adapted from two studies which examined treatment intensification.10, 11  Using 
these criteria, 7 patterns of care emerge (Supplemental I).  The rules were designed to replicate 
clinical practice and prevent overestimating opportunities while maximizing “credit” given to 
practitioners.     
Medication adherence 
Medications in the adherence assessment included the following classes: angiotensin converting 
enzyme inhibitor or receptor blocker; beta-blocker; diuretics (except furosemide); calcium 
channel blocker; centrally acting antihypertensive or alpha adrenergic antihypertensives.  
Furosemide was excluded given the potential for “as needed” use.11 
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Medication adherence was computed using the medication possession ratio (MPR) defined by 
Steiner and colleagues as a continuous, multiple-interval measure of medication availability.12, 13  
An average of all drugs’ MPRs within a therapeutic class was computed to produce one averaged 
MPR accounting for medication “stockpiling” ; average MPR was then dichotomized with non-
compliance defined as <0.8.14   We calculated for each patient an MPR as the ratio of the number 
of days with antihypertensive available divided by the medication eligible days.13, 15, 16 The MPR 
ranges from 0 to 1, and higher values indicate greater adherence.  For patients with 0 or 1 
antihypertensive medication fill, their MPR was considered missing.  
 
Statistical Analyses 
Covariates were chosen based on clinical significance and included: sex, race (white, black, 
other), number of antihypertensives prescribed at the index stroke, NIH stroke scale17 and 
Charlson co- morbidity score.18  We accounted for clustering of patients within medical centers 
because of the correlation of outcomes (level of hypertension control among patients from the 
same facility).   
 
We used a mixed-effects regression model to examine the average SBP trajectory of all patients 
from stroke discharge over the 1-year post stroke stratified by their last SBP at discharge 
(<140mmHg; 141 mmHg to < 160 mmHg; and >160 mmHg).  Then we analyzed treatment 
intensification among patients who had at least one elevated SBP (treatment opportunity) over 
the 1 year post stroke follow-up.  For these analyses, we excluded patients with controlled SBP 
during the follow-up period (no treatment opportunities).  We used linear regression to examine 
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the association between adherence (MPR) and treatment intensification. Statistical analyses were 
done using SAS for Windows 9.2. (SAS Institute, Cary, NC) 
 
RESULTS 
Of the 3965 ischemic stroke patients, we excluded cases (N=812 [20.4%]) for: in hospital 
mortality (N=152), hospice care (N=44) or no SBP values (N=616, Figure 1).  Sixty two percent 
(N=1956) of the 3153 patients in the sample had no opportunities for treatment intensification 
because SBP was <140mmHg in the year after stroke.  The remaining patients (N=1197) had at 
least one elevated SBP or a treatment intensification opportunity.  Patients in both groups were 
65 years-old and the majority were male (Table 1).  Patients without treatment intensification 
opportunities did not differ in age, NIH stroke scale, Charlson score or smoking status compared 
with those who had one or more intensification opportunities. A higher proportion of black 
patients (27.2%) had at least one intensification opportunity during follow-up versus those with 
no opportunities (20.6%). 
 
BP trajectory in the year after stroke 
Among the 3153 patients who were discharged from an ischemic stroke hospitalization; 1973 
(62.6%) had a discharge SBP < 140mmHg, 819 patients (26.0%) with SBP between 141 and 
160mmHg, and 361 patients (11.4%) with SBP >160mmHg (Table 2).  The average  SBP and 
DBP increased among each of these three groups, with no difference in the average number of 
clinic visits (mean 4.7, SD 3.8 p=0.18).  When adjusted for covariates, the discharge SBP 
strongly influenced SBP trajectory over the following year (Figure 2).   
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Treatment Intensification among those with Elevated SBP 
There were 1197 patients with at least one elevated SBP who had on average 6 clinic visits 
during follow-up.  Thirty percent of patients discharged with a SBP <140mmHg had an average 
1.93 opportunities for medication intensification. Forty seven percent of patients with discharge 
SBP between 141 and 160mmHg had an average of 2.1 opportunities for intensification and 63% 
of patients with a discharge SBP >160mmHg had an average of 2.4 intensification opportunities.  
Because the number of medication intensifications also increased; the proportion of clinically 
appropriate treatment intensifications was similar between the three categories, ranging from 58 
to 65% (p=0.15).  In other words, in about one-third of visits with elevated SBP, there was no 
evidence that medications were intensified. (Table 3)   
 
Relationship between adherence and treatment intensification  
Among patients with at least one intensification opportunity, approximately 48% were adherent 
(MPR >0.8) to their anti-hypertensive medications in the pre-stroke period and 46% were 
adherent in the post-stroke period. Alternatively, among those with an elevated SBP, more than 
50% had an MPR <0.8 (indicating low adherence).  There was no statistical difference in average 
MPR or in the proportion considered adherent across the three groups based on discharge SBP 
(Table 3).  No relationship between medication adherence and treatment intensification ratio was 
detected (p=0.71, Figure 3). Patients with an MPR of 1 (excellent adherence) had a treatment 
intensification ratio of 0% (indicating no medication changes).  Similarly, patients with an MPR 
of <0.3 (poor medication adherence) had treatment intensification ratios of 100% (every elevated 
SBP resulted in a medication change).   
 




We report three main findings.  First, among patients hospitalized for ischemic stroke, SBP 
trajectory post stroke was highly influenced by discharge SBP.   Second, regardless of discharge 
SBP, the ratio of medication intensification to opportunities is 58 to 65%.  An alternate 
interpretation is that we did not see evidence of medication titration in 35-42% of visits among 
post-stroke patients with elevated SBP values. Third, there was no relationship between post 
stroke medication adherence and treatment intensification evidenced by the ~50% of patients 
with an elevated SBP in the post stroke period had an adherence level of <80%.  This finding 
suggests that many patients would benefit from adherence counseling and that often providers do 
not account for or assess adherence when deciding to intensify treatment. 
 
Our results prompt three modifiable targets for improvement in stroke care.  Deficiencies in 
delivery of secondary prevention are common after cerebrovascular events.19-21  Hospital 
initiation of secondary prevention strategies is the standard of care for acute cardiac conditions 
and can improve risk factor control.22 As a result, the 2014 American Heart 
Association/American Stroke Association Guidelines for the Prevention of Stroke in Patients 
With Stroke and Transient Ischemic Attack emphasized initiation or resumption of hypertension 
treatment after the acute stroke period (24 to 48 hours) in neurologically stable patients with 
documented blood pressures  of >140/90 mmHg .5  Increased efforts to improve hypertension 
management prior to discharge (including re-initiation or modification of antihypertensives) 
could be highly beneficial to patients, given the robust relationship between discharge SBP and 
SBP trajectory post stroke in this study.   
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Second, efforts to assure that patients are on the correct medications and to titrate those 
medications should be implemented to avoid untreated/ undertreated hypertension.  At particular 
risk are those with resistant hypertension or black patients who are both more likely to be 
uncontrolled in the post stroke period, and may not have their medications changed or titrated.8, 
23  The lack of treatment intensification which we report are similar to those reported by Heisler 
et al.11  These investigators studied 38, 327 Veterans with hypertension; treatment intensification 
occurred at 30% of 68,610 elevated BP visits.  While we observed higher proportion of 
intensifications (58-65%), these investigators also found no relationship between intensification 
and medication adherence.   Another study by Rose et al.24 evaluated 819 patients with 
hypertension over 2 years.  They reported that adherent patients received more treatment 
intensification (approximately one intensification every 11 visits) compared to non- adherent 
patients.  However, patients with the worst adherence generally took approximately half their 
medication and any intensification resulted in blood pressure reductions.  Nevertheless, 
clinicians should assess a patients’ medication taking behavior and their self-efficacy for using 
medication at each treatment intensification decision.  
 
Finally, programs to improve anti-hypertensive medication adherence should be implemented.  
Many patients are discharged with instructions that include—“resume home regimen”. This 
home regimen is never revisited or modified despite the new risk factor of ischemic stroke.  
Additional counseling on adherence and evaluation of new barriers that may exist because of 
limitations resulting from the stroke should be addressed.   All of the above issues are 
preliminary steps in understanding and optimizing risk factor management among stroke 
patients.    




There are limitations to our study.  First, the population was mostly male Veterans admitted with 
ischemic stroke.  Hypertension management in the post-stroke period may not reflect the 
management of the general population.  However, we do not believe that providers in the private 
sector are systematically more or less aggressive in hypertension management than VHA 
providers.25-27 Our sample included persons with milder strokes and those discharged home; 
therefore our results may be more generalizable to this population.  It is also possible many 
patients received their antihypertensive care outside VHA, or that our treatment intensification 
algorithm missed patients with reasons for not intensifying therapy such as orthostatic 
hypotension. Similarly, we did not extensively review charts to determine if after discussion, 
patients and providers chose not to titrate medications (because of medication burden, dietary 
non adherence or patient-centered reasons).   Our intensification algorithms missed ~ 20% of the 
treatment intensifications in which the provider told the patient to increase their dose. This study 
was not designed to evaluate the appropriateness of the medication regimen nor whether patients 
had received comprehensive evaluations for the etiology of their hypertension (measurement of 
renin, aldosterone, or diagnostic testing such as renal artery imaging.)   Finally we utilized refill data as 
a proxy for medication taking and to calculate adherence.    
 
SUMMARY AND CONCLUSION 
SBP improves in the year after stroke; however, 12% of patients were discharged with 
SBP>160mmHg and many remained high in the year post stroke.  This population had no 
statistically significant difference in treatment intensification compared to patients who were 
discharged with lower SBP.  This finding suggests that the place to affect the most change in the 
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post stroke BP trajectory is prior to discharge.   Interventions to systematically improve 
modifiable risk factors should span inpatient and outpatient spectrum to deliver optimal patient 
care.    
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Figure 1: Flow of participants  
 
Figure 2: Systolic blood pressure trajectory in the year post stroke.* 
*Quadratic model adjusted for sex, race, Charlson score, number of antihypertensive drugs at 
discharge, and interactions for discharge blood pressure by time 
 
Figure 3: Medication possession ratio (adherence) and relationship to treatment intensification* 
*Relationship between adherence and treatment intensification p= 0.71. 
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Table 1: Patient characteristics by whether opportunity for treatment intensification existed 
during the follow-up (N=3153) 
 No blood pressure  
Opportunity N=1956 
At least one blood pressure 
opportunity N=1197 
Sex Males (%) 98.0 97.6 
Age, median (IQR) 65.0 (58.0, 76.0) 65.0 (58.0, 75.0) 
< 65 years, (%) 49.3 49.7 
65 - 74 years, (%) 22.3 24.1 







Black 20.6 27.2 
Other 6.9 7.3 
Missing race 7.5 7.0 






3-9 38.2 41.19 
10 + 8.3 5.10 
Current Smoker (%) 37.3 37.0 
Charlson Score (mean ±SD) 1 (0, 2) 1 (1, 2) 
Antihypertensives at discharge, median (IQR) 2 (1, 3) 2 (1, 3) 
Antihypertensive Class (%)   
None 9.6 5.2 
ACE/ARB 26.0 26.2 
Alpha-1 Antagonist 3.8 3.1 
Beta Blocker 22.8 22.4 
Calcium Channel Blocker 12.0 14.6 
Loop Diuretics 6.5 6.1 
Other antihypertensives 9.3 10.1 
Other Diuretic 10.1 12.2 
Discharged to home (%) 68.6 69.8 
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Table 2: 1-Year Follow-Up mean blood pressure, clinic visits and number of medications among 
ischemic stroke patients stratified by discharge blood pressure.   
* Eligible clinic visits include: general internal medicine; primary care/medicine; women’s 
health; mental health primary care; geriatrics; hypertension; cardiology; anticoagulation; 














Clinical Measures in the Year post-stroke 
Blood pressure at hospital Discharge 
Full cohort N=3153 








Systolic Blood Pressure, mmHg mean (SD)  126.1 (11.9) 136.8 (11.0) 146.5 (13.0) <0.001 
Diastolic Blood Pressure, mmHg mean (SD)  72.9 (9.9) 74.1 (9.9) 75.6 (10.7) <0.001 
Number of Outpatient Clinic visits*      
Mean (SD) 4.6 (4.1) 4.7 (3.8) 4.9 (3.6) 0.1850 
Antihypertensive Drugs at Discharge, median 
(IQR) 
2 (1, 3) 2 (1, 3) 2 (2, 4) <0.001 
Patients with at least one elevated blood 
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Table 3: 1-Year Follow-Up for patients with at least 1 elevated blood pressure opportunity by 
discharge blood pressure (n=1197).   
* Eligible clinic visits include: general internal medicine; primary care/medicine; women’s 
health; mental health primary care; geriatrics; hypertension; cardiology; anticoagulation; 
diabetes, endocrine, or metabolism; infectious disease; renal/nephrology; pulmonary, or chest; or 
neurology.  
† Comparison of pre versus post stroke medication possession ratio p value reported   




> 160 mmHg 
N=226 
P value 
Systolic Blood Pressure, mmHg mean (SD)  137.5 (8.9) 143.5 (9.7) 151.0 (12.3) <0.001 
Diastolic Blood Pressure, mmHg mean (SD)  78.4 (9.8) 77.7 (9.6) 78.4 (10.6) 0.519 
Number of Antihypertensives,  median (IQR) 2 (1, 3) 2 (1, 3) 3 (2, 4) <0.001 
Number of Eligible clinic visits*, mean (SD)  5.8 (5.4) 5.8 (4.6) 5.8 (3.8) 0.987 
Antihypertensive Intensifications     
Median IQR 1 (0, 2) 1 (1, 2) 1 (1, 2) 0.003 
Mean (SD) 1.13 (1.11)  1.23 (1.11) 1.46 (1.27) <0.001 
Intensification opportunities     
Median IQR 1 (1, 2) 2 (1, 3) 2 (1, 3) <0.001 
Mean (SD) 1.93 (1.54) 2.12 (1.45) 2.39 (1.64) <0.001 
Proportion of Intensifications to opportunities     
Mean (95% Confidence Interval) 58% (55, 62) 60% (55, 64) 65% (59, 70) 0.150 
Proportion with calculable Pre stroke 
Medication Possession Ratio (%) 
492/590 (83.4) 325/381 (85.3) 187/226 
(82.7) 
0.641 
Medication possession ratio, mean (SD) 0.74 (0.23) 0.73 (0.23) 0.75 (0.21) 0.725 
Medication possession ratio >0.8 (%) 47.8  47.1 49.7 0.905 
Proportion with calculable Post stroke 
Medication Possession Ratio (%) 
573/590 (97.1) 364/381 (95.5) 219/226 
(96.9) 
0.399 
Medication possession ratio, mean (SD) 0.74 (0.20) 0.76 (0.18) 0.76 (0.19) 0.190 
Medication possession ratio >0.8 (%) 46.4 45.6 46.6 0.963 
Pre-stroke/Post-stroke comparison† 0.937 0.047 0.944  
